Crossmark

One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry

Crossref DOI link: https://doi.org/10.1007/s00296-020-04762-7

Published Online: 2021-01-02

Published Print: 2021-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fellous, Safaa https://orcid.org/0000-0003-3219-5239
Rkain, Hanan https://orcid.org/0000-0001-7409-4765
Ahid, Samir https://orcid.org/0000-0002-7797-4722
Abouqal, Redouane https://orcid.org/0000-0002-6117-4341
Tahiri, Latifa https://orcid.org/0000-0001-9914-7675
Hmamouchi, Ihsane https://orcid.org/0000-0003-4402-5034
Achemlal, Lahsen https://orcid.org/0000-0002-9744-1368
El Bouchti, Imane https://orcid.org/0000-0003-1222-3407
El Maghraoui, Abdellah https://orcid.org/0000-0003-0668-5680
Ghozlani, Imad https://orcid.org/0000-0001-7966-4173
Hassikou, Hasna https://orcid.org/0000-0003-4190-1481
Harzy, Taoufik https://orcid.org/0000-0001-6275-4391
Ichchou, Linda https://orcid.org/0000-0002-2733-5594
Mkinsi, Ouafa https://orcid.org/0000-0001-8505-8479
Niamane, Radouane https://orcid.org/0000-0002-0472-2532
Bahiri, Rachid https://orcid.org/0000-0001-5677-1750
Allali, Fadoua https://orcid.org/0000-0001-9847-2142
License Information

Text and Data Mining valid from 2021-01-02

Version of Record valid from 2021-01-02
More Information

Article History

Received: 12 October 2020

Accepted: 24 November 2020

First Online: 2 January 2021

Compliance with ethical standards

:

: The authors declare they have no conflicts of interest.